Edwards Lifesciences (NYSE:EW) beat Q1 2026 earnings with $1.65 billion in revenue and adjusted EPS of $0.78, raising full-year guidance as TAVR and TMTT growth accelerate. A structural health leadership analysis.

Key Highlights

  • Q1 2026 revenue reached $1.65 billion, up 12.7% year-over-year, exceeding analyst estimates of $1.6 billion.
  • Adjusted EPS of $0.78 surpassed the $0.73 consensus forecast by 6.85%, signaling strong operational leverage.
  • TMTT segment revenue surged 42% year-over-year to $173 million, anchoring the company's long-term growth thesis.
  • Full-year 2026 total company sales growth guidance raised to 9%-11%, with adjusted EPS guidance of $2.95-$3.05.
  • A $500 million accelerated share repurchase was completed during the quarter.

A Focused Strategy Delivers

Edwards Lifesciences (NYSE:EW) opened fiscal 2026 with a quarter that reinforced the investment case for its concentrated structural heart strategy. Total revenue of $1.65 billion grew 12.7% year-over-year, clearing analyst expectations. Adjusted EPS of $0.78 beat the $0.73 forecast, while GAAP EPS came in at $0.66. Adjusted gross profit margin held at 78.2%, a marginal decline from 78.7% a year earlier, attributed to a weaker U.S. dollar and manufacturing costs linked to capacity expansion across new therapies.

CEO Bernard Zovighian positioned the result as evidence of structural durability: the company's 16,000 employees are executing across all product groups and geographies, with no acute capacity constraints reported across major health systems.

TAVR: Clinical Evidence Driving Category Expansion

The transcatheter aortic valve replacement segment generated $1.2 billion in Q1 2026, up 11% year-over-year, remaining the company's primary revenue pillar. Growth reflected broad market expansion rather than pure competitive displacement. The clinical community has increasingly embraced proactive management of severe aortic stenosis, a shift reinforced by long-term data from the EARLY TAVR, PARTNER 3 (seven-year), and PARTNER 2 (ten-year) trials, all of which validated the performance durability of the SAPIEN platform.

Average selling prices remained stable globally. Edwards gained modest share in Europe following a competitor's exit, and saw healthy U.S. TAVR growth above prior expectations. CMS is reconsidering the National Coverage Determination for TAVR, with a draft decision memo expected by June 15. A favorable policy outcome could meaningfully expand U.S. procedural access. Full-year TAVR guidance was raised to 7%-9%, from the prior range of 6%-8%.

TMTT: A Portfolio Maturing at Scale

The transcatheter mitral and tricuspid therapies segment posted $173 million in Q1, a 42% year-over-year increase and the most consequential near-term growth driver for the company's valuation outlook. Global mitral and tricuspid procedural volumes grew in double digits. EVOQUE, the tricuspid replacement system, drew clinical attention following presentation of two-year TRISCEND II data at the ACC Scientific Sessions, showing lower all-cause mortality versus medical treatment. PASCAL, the mitral and tricuspid repair platform, continued to gain adoption on the basis of its differentiated design characteristics.

SAPIEN M3, launched in the U.S. at year-end 2025 for mitral replacement, remains in early-stage commercial rollout, targeting patients for whom existing surgical or transcatheter repair options are inadequate. Management reiterated full-year 2026 TMTT guidance of $740-$780 million, representing 35%-45% growth, and maintained a longer-range objective of $2 billion in annual TMTT revenue by 2030.

Guidance, Capital Discipline, and Operating Leverage

Following Q1 outperformance, total company sales growth guidance for 2026 was raised to 9%-11%, implying revenues of $6.5-$6.9 billion. Adjusted EPS guidance moved to $2.95-$3.05. For Q2, management projected sales of $1.66-$1.74 billion and adjusted EPS of $0.70-$0.76. Full-year operating margin is expected at the high end of the original 28%-29% range, equating to approximately 150 basis points of constant-currency expansion. Cash and equivalents stood at $2.4 billion as of March 31, 2026, with approximately $1.5 billion remaining under the existing share repurchase authorization.

Risks Warrant Monitoring

Foreign exchange movements contributed approximately $49 million, or 400 basis points, to reported year-over-year revenue growth in Q1. Management now expects a full-year FX tailwind of roughly $55 million, the majority of which has already been realized. Any material reversal in currency conditions could compress reported results later in 2026. Competitive intensity in TMTT is rising, and the next-generation SAPIEN X4 TAVR platform remains in a confirmatory clinical trial phase through 2026, limiting near-term product differentiation to existing evidence. A CFO transition is also underway, with Scott Ullem continuing in his role while a successor is identified.

The Quarter's Signal for the Year Ahead

Edwards Lifesciences enters the balance of 2026 with momentum that appears structural rather than episodic. The convergence of durable clinical evidence, expanding procedural volumes, a scaling TMTT portfolio, and disciplined capital allocation frames a coherent growth narrative. The key test will be Q3 and Q4 performance against a strong 2025 second half, which set a higher comparable base. Near-term catalysts include the CMS NCD draft memo expected in June and PROGRESS trial data to be presented at TCT later in the year. Both carry potential to extend or complicate the current positive trajectory.